Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Fig. 1

Network plot of treatment comparisons for major adverse cardiovascular events (MACE) and all-cause mortality. a Categorized drugs comparisons for MACE; b Categorized drugs comparisons for all-cause mortality; c Individual drugs comparisons for MACE; d Individual drugs comparisons for all-cause mortality. The size of the nodes represents the number of trials that study the treatments. Direct comparison of treatments is linked with a line, the thickness of which represents the number of trials that assess the comparison. SGLT2i sodium-glucose co-transporter 2 inhibitor(s), GLP1ra glucagon-like peptide-1 receptor agonist(s), DPP4i dipeptidyl peptidase 4 inhibitor(s), TZD thiazolidinedione, MET metformin, SU sulfonylurea, INS insulin, PLA placebo, VIL vildagliptin, EMP empagliflozin, LIX lixisenatide, ALO alogliptin, EXE exenatide, LIR liraglutide, CAN canagliflozin, DAP dapagliflozin, DUL dulaglutide, SIT sitagliptin, LIN linagliptin, ALB albiglutide, SAX saxagliptin

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840